Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults

被引:15
作者
Derad, Inge [1 ]
Obermann, Birgit [2 ]
Katalinic, Alexander [3 ]
Eisemann, Nora [3 ]
Knobloch, Johannes K-M. [2 ]
Sayk, Friedhelm [4 ]
Wellhoener, Peter [1 ]
Lehnert, Hendrik [1 ]
Solbach, Werner [2 ]
Suefke, Sven [1 ]
Steinhoff, Juergen [1 ]
Nitschke, Martin [1 ]
机构
[1] Univ Lubeck, Dept Internal Med 1, Lubeck, Germany
[2] Univ Lubeck, Inst Med Microbiol, Lubeck, Germany
[3] Univ Lubeck, Dept Epidemiol, Lubeck, Germany
[4] Univ Lubeck, Dept Internal Med 2, Lubeck, Germany
关键词
chronic kidney disease; epidemiology and outcome; HUS; hypertension; kidney failure; proteinuria; STEC O104:H4; THERAPEUTIC PLASMA-EXCHANGE; RENAL-FUNCTION; RELATIVE NEPHROPROTECTION; VOLUME EXPANSION; SYNDROME HUS; SHORT-TERM; OUTBREAK; O104/H4; CHILDREN; GERMANY;
D O I
10.1093/ndt/gfv255
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Shiga toxin-producing, enteroaggregative Escherichia coli was responsible for the 2011 outbreak of haemolytic uraemic syndrome (HUS). The present single-centre, observational study describes the 1-year course of the disease with an emphasis on kidney function. Outcome data after 1 year are associated with treatment and patient characteristics at onset of HUS. Methods. Patients were treated according to a standardized approach of supportive care, including a limited number of plasmapheresis. On top of this treatment, patients with severe HUS (n = 35) received eculizumab, a humanized anti-C5 monoclonal antibody inhibiting terminal complement activation. The per-protocol decision-to start or omit an extended therapy with eculizumab accompanied by azithromycinseparated the patients into two groups and marked Day 0 of the prospective study. Standardized visits assessed the patients' well-being, kidney function, neurological symptoms, haematological changes and blood pressure. Results. Fifty-six patients were regularly seen during the followup. All patients had survived without end-stage renal disease. Young(er) age alleviated restoring kidney function after acute kidney injury even in severe HUS. After 1 year, kidney function was affected with proteinuria [26.7%; 95% confidence interval (CI) 13.8-39.6], increased serum creatinine (4.4%, CI 0.0-10.4), increased cystatin C (46.7%, CI 32.1-61.3) and reduced (<90 mL/min) estimated glomerular filtration rate (46.7%, CI 32.1-61.3). Nine of the 36 patients without previous hypertension developed de novo hypertension (25%, CI 10.9-39.1). All these patients had severe HUS. Conclusions. Although shiga toxin-producing Escherichia coli (STEC)-HUS induced by O104:H4 was a life-threatening acute disease, follow-up showed a good recovery of organ function in all patients. Whereas kidney function recovered even after longer duration of dialysis, chronic hypertension developed after severe HUS with neurological symptoms and could not be prevented by the extended therapy.
引用
收藏
页码:95 / 103
页数:10
相关论文
共 42 条
[1]   Relative nephroprotection during Escherichia coli O157:H7 infections:: Association with intravenous volume expansion [J].
Ake, JA ;
Jelacic, S ;
Ciol, MA ;
Watkins, SL ;
Murray, KF ;
Christie, DL ;
Klein, EJ ;
Tarr, PI .
PEDIATRICS, 2005, 115 (06) :E673-E680
[2]  
[Anonymous], 2011, BERICHT ABSCHLIESSEN
[3]   Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study [J].
Bielaszewska, Martina ;
Mellmann, Alexander ;
Zhang, Wenlan ;
Koeck, Robin ;
Fruth, Angelika ;
Bauwens, Andreas ;
Peters, Georg ;
Karch, Helge .
LANCET INFECTIOUS DISEASES, 2011, 11 (09) :671-676
[4]   German Outbreak of Escherichia coli O104:H4 Associated with Sprouts [J].
Buchholz, Udo ;
Bernard, Helen ;
Werber, Dirk ;
Boehmer, Merle M. ;
Remschmidt, Cornelius ;
Wilking, Hendrik ;
Delere, Yvonne ;
an der Heiden, Matthias ;
Adlhoch, Cornelia ;
Dreesman, Johannes ;
Ehlers, Joachim ;
Ethelberg, Steen ;
Faber, Mirko ;
Frank, Christina ;
Fricke, Gerd ;
Greiner, Matthias ;
Hoehle, Michael ;
Ivarsson, Sofie ;
Jark, Uwe ;
Kirchner, Markus ;
Koch, Judith ;
Krause, Gerard ;
Luber, Petra ;
Rosner, Bettina ;
Stark, Klaus ;
Kuehne, Michael .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (19) :1763-1770
[5]   Long term risk for hypertension, renal impairment, and cardiovascular disease after gastroenteritis from drinking water contaminated with Escherichia coli O157:H7: a prospective cohort study [J].
Clark, William F. ;
Sontrop, Jessica M. ;
Macnab, Jennifer J. ;
Salvadori, Marina ;
Moist, Louise ;
Suri, Rita ;
Garg, Amit X. .
BMJ-BRITISH MEDICAL JOURNAL, 2010, 341 :1089
[6]   Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study [J].
Colic, Edin ;
Dieperink, Hans ;
Titlestad, Kjell ;
Tepel, Martin .
LANCET, 2011, 378 (9796) :1089-1093
[7]   Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab [J].
Delmas, Yahsou ;
Vendrely, Benoit ;
Clouzeau, Benjamin ;
Bachir, Hiba ;
Hoang-Nam Bui ;
Lacraz, Adeline ;
Helou, Sebastien ;
Bordes, Cecile ;
Reffet, Armel ;
Llanas, Brigitte ;
Skopinski, Sophie ;
Rolland, Patrick ;
Gruson, Didier ;
Combe, Christian .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 (03) :565-572
[8]   Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak [J].
Dundas, S ;
Murphy, J ;
Soutar, RL ;
Jones, GA ;
Hutchinson, SJ ;
Todd, WTA .
LANCET, 1999, 354 (9187) :1327-1330
[9]  
EMA: European Medicines Agency, 2012, SOL EPAR PROD INF SO
[10]   Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome - A systematic review, meta-analysis, and meta-regression [J].
Garg, AX ;
Suri, RS ;
Barrowman, N ;
Rehman, F ;
Matsell, D ;
Rosas-Arellano, MP ;
Salvadori, M ;
Haynes, RB ;
Clark, WF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (10) :1360-1370